CNTG News and Press, Centogene N.V. From 12/13/23

2023-12-13 10:00:34 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Motus GI, C4 T...

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the Company reached its initial recruitment and genetic testing mi...

Lifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing services to patients, health systems, biopharma clients, and research institutions across the Gulf Cooperation Council (GCC) region CENTOGENE to recei...

Collaborative research initiative leveraged CENTOGENE’s Whole Exome Sequencing (WES) to reveal disease-causing gene called ACBD6 (Acyl-CoA Binding Domain Containing 6) Over seven years, a total of 45 affected individuals from 29 independent families in Southeast Asia, Central A...

2023-10-31 13:28:44 ET Gainers: SciSparc Ltd SPRC +65% . Cardio Diagnostics Holdings ( CDIO ) +54% . Alpha Technology Group Limited ATGL +50% . Centogene ( CNTG ) +30% . Pop Culture Group Co Ltd ( CPOP ) +30% . American Acquisition O...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the expansion of MOx, the Company’s multiomic diagnosti...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that CENTOGENE CEO Kim Stratton will present in the virtual track ...

2023-09-07 17:16:37 ET More on Centogene Seeking Alpha’s Quant Rating on Centogene Historical earnings data for Centogene Financial information for Centogene Centogene receives Nasdaq non-compliance notification For further details see: Cen...

First half 2023 total revenues with double-digit growth of 15.1% at €24.6 million Both Pharma and Diagnostics segments deliver strong performance, reaffirming full year 2023 guidance for total revenue growth between 10% to 15% Recently announced strategic collaboration with Lifera,...

Results from pivotal study published in Diagnostics journal Confirmation of utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher disease Could predict clinical course of patients and improve personalized care CAMBRIDGE, Mass. and ROSTOCK, Germany and ...